Immunologix, GenScript form human antibody therapeutics partnership

Immunologix holds the exclusive worldwide license rights to a proprietary technique used to produce fully human antibodies.

GenScript claimed that it offers antibody drug services that include antigen production, hybridoma development and stabilisation, antibody sequencing, chimeric antibody, antibody humanisation, affinity maturation, epitope mapping, antibody and protein characterisation, in-vitro assay and screening, in-vivo efficacy and safety study, antibody transient expression, stable cell line, and scale up production.

Immunologix founder and chief operating officer Ryan Fiorini said that the relationship between Immunologix and GenScript has been building since initial discussions began in July 2010.

"Having this partnership allows both parties to offer their clients a 100% fully human monoclonal antibody ready for clinical trials," Fiorini said.

GenScript vice president Nick Yan said that GenScript is pleased to form the strategic alliance with Immunologix.

"The partnership provides GenScript the access to Immunologix’ proprietary technology and complements its antibody drug development service platform," Yan said.

"Jointly, we can offer one-stop solutions and complete portfolios to our clients for all their needs in human therapeutic antibody from target identification to clinic candidates cost-effectively and time-efficiently."